ASX-Dividend-Report-Banner
Sponsored

Imugene’s (ASX: IMU) HER - Vaxx and CHECKVacc to feature at ESMO Congress

July 24, 2023 11:27 AM AEST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Imugene’s (ASX: IMU) HER - Vaxx and CHECKVacc to feature at ESMO Congress
Image source: Company PPT

Highlights

  • Imugene’s oncolytic virotherapy platform and B cell immunotherapy are to be presented at the ESMO Congress.
  • ESMO Congress is amongst the most influential oncology platforms globally.
  • The oncology event is to be held in Madrid during 20-24 October 2023.

ASX-listed clinical-stage immune-oncology company Imugene Limited (ASX: IMU) shared that its cancer therapy platforms HER - Vaxx and CHECKVacc will be featured at the ESMO (European Society for Medical Oncology) Congress. The event will take place in Madrid on 20-24 October 2023.

The ESMO Congress is one of the prominent oncology platforms for journalists, healthcare industry representatives, patient advocates, clinicians, researchers and journalists.

Imugene will feature in the following poster sessions:

HER - Vaxx is a B cell immunotherapy, and CHECKVacc is a CF33 oncolytic virotherapy being developed by Imugene.

Shares up ~4%

Following the update, the share price of IMU increased by 3.191% to trade at AU$0.097 per share at the time of writing on 24 July 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.